Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS

Bristol Myers Squibb and Acceleron Pharma have secured FDA approval for Reblozyl to treat anaemia with lower-risk MDS. (Credit: Rept0n1x)